December 22, 2015
A Tennessee federal judge gave his final approval Tuesday for a $9 million agreement reached between Mutual Pharmaceutical Co. Inc. and an end-payor class to settle claims the company colluded with Pfizer Inc. unit King Pharmaceuticals Inc. to delay generic versions of the muscle relaxant Skelaxin, saying it was fair.
November 12, 2015
King Pharmaceuticals LLC contended Thursday that Walgreens Boots Alliance Inc., Safeway Inc., Rite Aid Corp. and several other retailers cannot sue the Pfizer Inc. unit over an alleged pay-for-delay scheme over Skelaxin because King never sold them the muscle relaxant.
August 13, 2014
Attorneys for end-payor plaintiffs accusing Mutual Pharmaceutical Co. Inc. of colluding with King Pharmaceuticals Inc. to delay generic versions of the muscle relaxant Skelaxin asked a Tennessee federal court to grant them $3 million in fees on Tuesday, arguing that the litigation's risks and difficulties merited the award.
July 15, 2014
Mutual Pharmaceutical Co. Inc. has agreed to pay $9 million to settle claims brought by a proposed class of end-payors claiming the company colluded with Pfizer Inc. unit King Pharmaceuticals Inc. to delay generic versions of the muscle relaxant Skelaxin, according to documents filed in Tennessee federal court.
June 30, 2014
A Tennessee federal judge on Monday approved $24.3 million in attorneys' fees after a Pfizer Inc. unit and others reached a $73 million settlement with a class of drug wholesalers who claimed they violated antitrust laws through a pay-for-delay deal over the muscle relaxant Skelaxin.
May 29, 2014
A group of pharmacies urged a Tennessee federal judge on Wednesday to approve a $2 million settlement by Mutual Pharmaceutical Co. Inc. over multidistrict claims that Mutual was part of a pay-for-delay deal that suppressed generic competition for Skelaxin, a Pfizer Inc. muscle relaxant.
May 20, 2014
A Tennessee federal judge ruled Tuesday that BlueCross BlueShield of Tennessee Inc.'s case accusing a Pfizer Inc. unit and Mutual Pharmaceutical Co. of colluding to block generic versions of the muscle relaxant Skelaxin with baseless patent suits didn't present substantial federal issues, sending the case to state court.
April 30, 2014
A unit of Pfizer Inc. and generic drugmaker Mutual Pharmaceutical Co. have agreed to pay $73 million to settle a lawsuit brought by a class of drug wholesalers who accused the companies of violating antitrust laws in a pay-for-delay deal over muscle relaxant Skelaxin, according to documents filed Wednesday in Tennessee federal court.
March 11, 2014
To shut down a pay-for-delay class action against Pfizer Inc.'s King Pharmaceuticals Inc. and generic-drug maker Mutual Pharmaceutical Co. Inc., attorneys from Kaye Scholer LLP and Munger Tolles & Olson LLP had to figure out how to explain why the U.S. drug distribution system didn't fit the traditional antitrust class certification model. For the defense team, that meant leading with a complex economic story and trusting the judge to come along for the ride.
February 14, 2014
A group of pharmacies urged a Tennessee federal judge on Wednesday to reconsider his refusal to certify classes of drug retailers targeting a pay-for-delay deal that suppressed competition to a muscle relaxant made by a unit of Pfizer Inc., saying the similarities among the class members outweighed the differences.